ABSTRACT
Background: in recent years, n-3 PUFAs have been confirmed to be associated with cardiovascular and cerebrovascular diseases, but the link between n-3 PUFAs and stroke remains controversial. Objective: this study aimed to evaluate the association between n-3 PUFAs and stroke. Methods: we performed a comprehensive search of the following electronic databases: PubMed, Embase, Cochrane Library, Web of Science and CNKI. Literature screening and quality assessment were performed according to inclusion and exclusion criteria. Cochrane's tool was used to assess the methodological components of each study, and the Stata 15.1 software was used to perform the meta-analysis. Results: a total of 18 RCTs were included, and the meta-analysis showed no differences in vascular disease-related death between the n-3 PUFA and control groups (RR, 0.95, 95 % CI: 0.89 to 1.01, p = 0.114 > 0.05). However, there was a significant difference in the lower n-3 PUFA dose subgroup (RR, 0.93, 95 % CI: 0.87 to 0.99, p = 0.034 < 0.05). Oral administration of n-3 PUFAs did not significantly reduce the risk of the following cerebrovascular accidents: stroke (RR = 1.00, 95 % CI: 0.93 to 1.07, p = 0.983 > 0.05), ischemic stroke (RR = 0.99, 95 % CI: 0.896 to 1.094, p = 0.841 > 0.05), hemorrhagic stroke (RR = 1.249, 95 % CI: 0.939 to 1.662, p = 0.127 > 0.05) and TIA (RR = 1.016, 95 % CI: 0.882 to 1.170, p = 0.824 > 0.05). The levels of TC (SMD, -0.167, 95 % CI: −0.193 to -0.141, p = 0 < 0.05) and TG (SMD, -0.065, 95 % CI: -0.087 to -0.042, p = 0 < 0.05) in the n-3 PUFA group were significantly decreased, but no significant improvement in the LDL (SMD, 0.022, 95 % CI: 0.005 to 0.040, p = 0.889 > 0.05) and HDL (SMD, 0.008, 95 % CI: -0.009 to 0.025, p = 0.368 > 0.05) levels was observed. Conclusion: this systematic review and meta-analysis suggests that treatment with low-dose n-3 PUFAs can reduce cerebrovascular disease-related death. After the oral administration of n-3 PUFAs (AU)
Antecedentes: en los últimos años se ha confirmado que los AGPI n-3 se relacionan con las enfermedades cardiovasculares y cerebrovasculares, pero el vínculo entre los AGPI n-3 y el ictus sigue siendo objeto de controversia. Objetivo: este estudio se propuso evaluar la relación entre AGPI n-3 e ictus. Métodos: se realizaron búsquedas en las siguientes bases de datos electrónicas: PubMed, Embase, Cochrane Library, Web of Science y CNKI. Se utilizó la herramienta de Cochrane para evaluar los componentes metodológicos de cada estudio y el software Stata para el metanálisis. Resutados: se incluyeron 18 ECA y el metanálisis no mostró diferencias en cuanto a la muerte relacionada con enfermedades vasculares entre los grupos de AGPI n-3 y de control (RR: 0,95, IC del 95 %: 0,89 a 1,01). Sin embargo, hubo una diferencia significativa en el subgrupo de dosis más baja de AGPI n-3 (RR: 0,93, IC del 95 %: 0,87 a 0,99). La administración oral de AGPI n-3 no redujo significativamente el riesgo de los siguientes accidentes cerebrovasculares: ictus (RR = 1,00, IC 95 %: 0,93 a 1,07), ictus isquémico (RR = 0,99, IC 95 %: 0,896 a 1. 094), ictus hemorrágico (RR = 1,249, IC 95 %: 0,939 a 1,662) y AIT (RR = 1,016, IC 95 %: 0,882 a 1,170). Los niveles de TC (DME: -0,167, IC del 95 %: -0,193 a 0,141) y TG (DME -0,065, IC del 95 %: -0,087 a -0,042) en el grupo de AGPI n-3 se redujeron significativamente, pero no hubo una mejora significativa en los niveles de LDL (SMD: 0,022, IC 95 %: 0,005 a 0,040) y HDL (SMD: 0,008, IC 95 %: -0,009 a 0,025). Conclusiones: esta revisión sistemática y metaanálisis sugiere que el tratamiento con PUFA n-3 en dosis bajas puede reducir la muerte relacionada con la enfermedad cerebrovascular. Después de la administración oral de PUFA n-3, los niveles de TC y TG disminuyeron significativamente, pero los PUFA n-3 no impidieron la aparición de accidentes cerebrovasculares ni mejoraron los niveles de LDL o HDL (AU)
Subject(s)
Humans , Fatty Acids, Omega-3/therapeutic use , Stroke/prevention & control , Secondary PreventionABSTRACT
Objective:To observe the clearance strategies of hemiplegic stroke survivors with foot drop.Methods:Thirty hemiplegic stroke survivors with foot drop formed the observation group and 30 healthy counterparts constituted the control group. A three-dimensional motion capture system was used to observe and compare the minimum toe clearance (MTC) and its variability between the two groups to draw the motion trajectory of the toe in the swing phase of their gaits. The gait parameters were correlated with the toe clearance.Results:The average MTC of the observation group subjects on both the hemiplegic and non-hemiplegic side (12.01±3.36 and 22.38±5.51mm) was significantly smaller than the control group′s averages. The variability of their MTCs on both sides was also significantly greater. Clearance on the hemiplegic side was significantly less and its variability was significantly greater. Among the observation group, MTC on the hemiplegic side was positively correlated with walking speed, step length, swing phase percentage, maximum angle of hip extension, maximum angle of knee flexion, maximum angle of ankle dorsiflexion, and the range of motion of the knee and ankle joints.Conclusions:Hemiplegic stroke survivors with foot drop walk unstably with little toe clearance. It is necessary to intervene at the hip, knee and ankle to improve their obstacle clearance.
ABSTRACT
Objective:To observe and analyze the effect of double and single bridge exercise on the electromyographic activities of related core muscle groups in stroke patients, and to explore its rules and characteristics.Methods:A prospective cohort study was conducted on 40 stroke patients hospitalized in the Department of rehabilitation medicine, Hefei second people's Hospital, Anhui Province from March 2020 to May 2021.The surface electromyography (sEMG) instrument was used to collect the surface electromyographic signals of erector spinalis, rectus abdominis, gluteus maximus and biceps femoris during double and single bridge exercise, and the root mean square (RMS) and integrated electromyography (iEMG) of the time domain indexes were analyzed. The measurement data conforming to normal distribution was expressed in xˉ± s.The non normal distribution data was expressed in M (Q1, Q3). Wilcoxon rank sum test was used to compare the difference between the two groups. Results:There was significant difference between RMS (30.0 (21.3, 45.5) μV vs. 24.0 (14.0, 35.8) μV) and IEMG (15.5. (10.0, 23.0) μV?s vs. 9.0 (5.0, 13.0) μV?s s) values of gluteus maximus on the healthy side and the affected side during double bridge exercise ( Z values were 2.07, 4.19; P values were 0.039, <0.001, respectively). There was significant difference in RMS (31.0 (15.3, 70.0) μV ratio of the healthy and affected biceps femoris 17.0 (11.0, 28.8) μV) and IEMG (14.5 (8.0, 26.5) μV?s vs. 7.0 (5.0, 10.8) μV?s) values of biceps femoris on the healthy side during double bridge exercise ( Z values were 3.44, 3.64; P values were 0.001 and <0.001, respectively ). There was significant difference between RMS(38.5(32.3, 46.0) μV vs. 35.0(22.3, 43.0) μV) and IEMG (16.5(12.0, 22.8) μV?s vs. 12.0(7.0, 21.0) μV?s) values of the gluteus maximus on the healthy side during single bridge exercise ( Z values were 2.24, 2.45; P values were 0.025, 0.014, respectively). There was significant difference between RMS (38.0 (15.3, 70.0) μV vs. 19.0 (12.0, 35.5) μV) and IEMG (16.0 (10.0, 27.0) μV?s vs. 6.5 (5.0, 12.5) μV?s s) values of biceps femoris on the healthy side during single bridge exercise ( Z values were 2.98,4.34; P values were 0.003 and <0.001, respectively). There was significant difference between RMS (24.0 (14.0, 35.8) μV vs. 35.0 (22.3, 43.0) μV) and IEMG (9.0 (5.0, 13.0) μV?s vs. 12.0 (7.0, 21.0) μV?s) values of double and single gluteus maximus on the affected side ( Z values were 2.24, 1.99; P values were 0.025,0.047, respectively). Conclusion:Double bridge and single bridge exercise could improve the related core muscle groups of stroke patients with hemiplegia, and single bridge was better than double bridge for the activation of gluteus maximus
ABSTRACT
Objective:To introduce a programmed death-1 (PD-1) inhibitor nivolumab used as a new antitumor agent. Methods:According to the literatures, the action mechanism of nivolumab and the clinical trial results on the main indications approved or being investigated in phase III trials were reviewed and evaluated. Results:Nivolumab could restore the antitumor activity of T cells through binding with PD-1 and consequently blocking its interaction with the key ligands of PD-L1 and PD-L2. Several completed and ongoing clinical trials showed that nivolumab used alone or combined with chemotherapy or CTLA-4 inhibitor ipilimumab exhibited better effica-cy when compared with current clinical used chemotherapy drugs in the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma. Nivolumab was well tolerated during the treatment with such main grade 3-4 adverse events as immune-mediated pneu-monia, abnormal liver functions and fatigue. Conclusion:Through its anti-tumor immune response, nivolumab can improve the clinical efficacy in the treatment of various tumors including melanoma, non-small cell lung cancer and renal cell carcinoma.
ABSTRACT
OBJECTIVE: To develop a RP-HPLC method for a simultaneously determination of the contents of sirolimus and probucol in the mixed-eluting stents. METHODS: Kromasil C18 column was used as an analytical column; the mobile phase consisted of acetonitrile and water which eluted by a gradient procedure at a flow rate of 1.0 mL?min-1. The detection wavelength was 277 nm; the column temperature was 55 ℃ and the sample size was 20 ?L. RESULTS: The calibration curves of sirolimus and probuol were linear in the range of 1.0～20.0 ?g?mL-1 (r=0.999 9). The average recoveries were 99.47%and 98.35%, respectively, with intra-day RSD and inter-day RSD all less than 5%. CONCLUSION: The method is simple, accurate and can be used to determine the contents of of sirolimus and probucol in the mixed-eluting stents.
